Breast cancers as ecosystems: a metabolic perspective.
Adipocytes
Glycolysis
Metabolism
Metastasis
Microbiota
Microenvironment
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
10 Aug 2023
10 Aug 2023
Historique:
received:
01
06
2023
accepted:
28
07
2023
revised:
18
07
2023
medline:
11
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
Breast cancer (BC) is the most frequently diagnosed cancer and one of the major causes of cancer death. Despite enormous progress in its management, both from the therapeutic and early diagnosis viewpoints, still around 700,000 patients succumb to the disease each year, worldwide. Late recurrency is the major problem in BC, with many patients developing distant metastases several years after the successful eradication of the primary tumor. This is linked to the phenomenon of metastatic dormancy, a still mysterious trait of the natural history of BC, and of several other types of cancer, by which metastatic cells remain dormant for long periods of time before becoming reactivated to initiate the clinical metastatic disease. In recent years, it has become clear that cancers are best understood if studied as ecosystems in which the impact of non-cancer-cell-autonomous events-dependent on complex interaction between the cancer and its environment, both local and systemic-plays a paramount role, probably as significant as the cell-autonomous alterations occurring in the cancer cell. In adopting this perspective, a metabolic vision of the cancer ecosystem is bound to improve our understanding of the natural history of cancer, across space and time. In BC, many metabolic pathways are coopted into the cancer ecosystem, to serve the anabolic and energy demands of the cancer. Their study is shedding new light on the most critical aspect of BC management, of metastatic dissemination, and that of the related phenomenon of dormancy and fostering the application of the knowledge to the development of metabolic therapies.
Identifiants
pubmed: 37561190
doi: 10.1007/s00018-023-04902-9
pii: 10.1007/s00018-023-04902-9
pmc: PMC10415483
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
244Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 22811
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 27516
Organisme : Fondazione Piemontese per la Ricerca sul Cancro
ID : PTCRC-INTRA 2020
Informations de copyright
© 2023. The Author(s).
Références
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
pubmed: 21376230
Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31–46
pubmed: 35022204
Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
pubmed: 33538338
Allison KH (2012) Molecular pathology of breast cancer: what a pathologist needs to know. Am J Clin Pathol 138(6):770–780
pubmed: 23161709
Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70
Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874
pubmed: 11553815
pmcid: 58566
Mahendralingam MJ et al (2021) Mammary epithelial cells have lineage-rooted metabolic identities. Nat Metab 3(5):665–681
pubmed: 34031589
Landskroner-Eiger S et al (2010) Morphogenesis of the developing mammary gland: stage-dependent impact of adipocytes. Dev Biol 344(2):968–978
pubmed: 20599899
pmcid: 2917626
Inman JL et al (2015) Mammary gland development: cell fate specification, stem cells and the microenvironment. Development 142(6):1028–1042
pubmed: 25758218
Wu Y et al (2022) Adipose tissue-to-breast cancer crosstalk: Comprehensive insights. Biochim Biophys Acta Rev Cancer 1877(5):188800
pubmed: 36103907
Brown KA (2021) Metabolic pathways in obesity-related breast cancer. Nat Rev Endocrinol 17(6):350–363
pubmed: 33927368
pmcid: 10410950
Semenza GL (2007) Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007(407):cm8
pubmed: 17925579
Wicks EE, Semenza GL (2022) Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest 132(11):e159839
Liao C et al (2023) Tumor hypoxia: from basic knowledge to therapeutic implications. Semin Cancer Biol 88:172–186
pubmed: 36603793
Semenza GL (2016) The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim Biophys Acta 1863(3):382–391
pubmed: 26079100
Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20(1):51–56
pubmed: 19942427
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033
pubmed: 19460998
pmcid: 2849637
Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11(5):325–337
pubmed: 21508971
DeBerardinis RJ, Chandel NS (2020) We need to talk about the Warburg effect. Nat Metab 2(2):127–129
pubmed: 32694689
Kim J, DeBerardinis RJ (2019) Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab 30(3):434–446
pubmed: 31484055
pmcid: 6730674
Ju YS et al (2014) Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife 3:e02935
pubmed: 25271376
pmcid: 4371858
Pavlides S et al (2009) The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8(23):3984–4001
pubmed: 19923890
Cai TQ et al (2008) Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res Commun 377(3):987–991
pubmed: 18952058
Liu C et al (2009) Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J Biol Chem 284(5):2811–2822
pubmed: 19047060
Ahmed K et al (2010) An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metab 11(4):311–319
pubmed: 20374963
Zhang D et al (2019) Metabolic regulation of gene expression by histone lactylation. Nature 574(7779):575–580
pubmed: 31645732
pmcid: 6818755
Dhup S et al (2012) Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des 18(10):1319–1330
pubmed: 22360558
Hirschhaeuser F, Sattler UG, Mueller-Klieser W (2011) Lactate: a metabolic key player in cancer. Cancer Res 71(22):6921–6925
pubmed: 22084445
Certo M et al (2021) Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol 21(3):151–161
pubmed: 32839570
Brooks GA (2018) The science and translation of lactate shuttle theory. Cell Metab 27(4):757–785
pubmed: 29617642
Ippolito L et al (2019) Lactate: a metabolic driver in the tumour landscape. Trends Biochem Sci 44(2):153–166
pubmed: 30473428
DeBerardinis RJ et al (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104(49):19345–19350
pubmed: 18032601
pmcid: 2148292
Wise DR et al (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105(48):18782–18787
pubmed: 19033189
pmcid: 2596212
Nicklin P et al (2009) Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136(3):521–534
pubmed: 19203585
pmcid: 3733119
Altman BJ, Stine ZE, Dang CV (2016) From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer 16(10):619–634
pubmed: 27492215
pmcid: 5484415
Zhang J, Pavlova NN, Thompson CB (2017) Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. EMBO J 36(10):1302–1315
pubmed: 28420743
pmcid: 5430235
Yang M, Vousden KH (2016) Serine and one-carbon metabolism in cancer. Nat Rev Cancer 16(10):650–662
pubmed: 27634448
Kandasamy P et al (2018) Amino acid transporters revisited: New views in health and disease. Trends Biochem Sci 43(10):752–789
pubmed: 30177408
Commisso C et al (2013) Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497(7451):633–637
pubmed: 23665962
pmcid: 3810415
Muranen T et al (2017) Starved epithelial cells uptake extracellular matrix for survival. Nat Commun 8:13989
pubmed: 28071763
pmcid: 5234072
Olivares O et al (2017) Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun 8:16031
pubmed: 28685754
pmcid: 5504351
Katheder NS et al (2017) Microenvironmental autophagy promotes tumour growth. Nature 541(7637):417–420
pubmed: 28077876
pmcid: 5612666
Sousa CM et al (2016) Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536(7617):479–483
pubmed: 27509858
pmcid: 5228623
Vera-Ramirez L et al (2018) Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun 9(1):1944
pubmed: 29789598
pmcid: 5964069
Snaebjornsson MT, Janaki-Raman S, Schulze A (2020) Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab 31(1):62–76
pubmed: 31813823
Hoy AJ, Nagarajan SR, Butler LM (2021) Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat Rev Cancer 21(12):753–766
pubmed: 34417571
Broadfield LA et al (2021) Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell 56(10):1363–1393
pubmed: 33945792
Koundouros N, Poulogiannis G (2020) Reprogramming of fatty acid metabolism in cancer. Br J Cancer 122(1):4–22
pubmed: 31819192
Kuhajda FP et al (1994) Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91(14):6379–6383
pubmed: 8022791
pmcid: 44205
Ricoult SJ et al (2016) Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. Oncogene 35(10):1250–1260
pubmed: 26028026
Swinnen JV et al (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98(1):19–22
pubmed: 11857379
Cancer Genome Atlas Research N (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456):43–49
Calvisi DF et al (2011) Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 140(3):1071–1083
pubmed: 21147110
Tao BB et al (2013) Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade. J Clin Neurosci 20(5):717–720
pubmed: 23416128
Corbet C et al (2016) Acidosis drives the reprogramming of fatty acid metabolism in cancer cells through changes in mitochondrial and histone acetylation. Cell Metab 24(2):311–323
pubmed: 27508876
Camarda R et al (2016) Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med 22(4):427–432
pubmed: 26950360
pmcid: 4892846
Padanad MS et al (2016) Fatty acid oxidation mediated by Acyl-CoA synthetase long chain 3 is required for mutant KRAS lung tumorigenesis. Cell Rep 16(6):1614–1628
pubmed: 27477280
pmcid: 4981512
Liu PP et al (2016) Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. Oncogene 35(43):5663–5673
pubmed: 27065330
pmcid: 5064824
Pascual G et al (2017) Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541(7635):41–45
pubmed: 27974793
Young RM et al (2013) Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev 27(10):1115–1131
pubmed: 23699409
pmcid: 3672646
Guillaumond F et al (2015) Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci USA 112(8):2473–2478
pubmed: 25675507
pmcid: 4345573
Ladanyi A et al (2018) Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene 37(17):2285–2301
pubmed: 29398710
pmcid: 5920730
Yan H et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773
pubmed: 19228619
pmcid: 2820383
Parsons DW et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812
pubmed: 18772396
pmcid: 2820389
Mardis ER et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361(11):1058–1066
pubmed: 19657110
pmcid: 3201812
DeBerardinis RJ, Chandel NS (2016) Fundamentals of cancer metabolism. Sci Adv 2(5):e1600200
pubmed: 27386546
pmcid: 4928883
Faubert B, Solmonson A, DeBerardinis RJ (2020) Metabolic reprogramming and cancer progression. Science 368(6487):eaaw5473
pubmed: 32273439
pmcid: 7227780
Perez-Castro L et al (2023) Tryptophan and its metabolites in normal physiology and cancer etiology. FEBS J 290(1):7–27
pubmed: 34687129
Kottakis F et al (2016) LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature 539(7629):390–395
pubmed: 27799657
pmcid: 5988435
Mayers JR et al (2016) Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353(6304):1161–1165
pubmed: 27609895
pmcid: 5245791
Shi X et al (2017) The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Adv 3(11):eaao5268
pubmed: 29109980
pmcid: 5665593
Yuneva MO et al (2012) The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab 15(2):157–170
pubmed: 22326218
pmcid: 3282107
Dienel GA, Cruz NF (2016) Aerobic glycolysis during brain activation: adrenergic regulation and influence of norepinephrine on astrocytic metabolism. J Neurochem 138(1):14–52
pubmed: 27166428
Cheng SC et al (2014) mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345(6204):1250684
pubmed: 25258083
pmcid: 4226238
De Bock K et al (2013) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154(3):651–663
pubmed: 23911327
Vaishnavi SN et al (2010) Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci USA 107(41):17757–17762
pubmed: 20837536
pmcid: 2955101
Bhattacharya D, Azambuja AP, Simoes-Costa M (2020) Metabolic reprogramming promotes neural crest migration via Yap/Tead signaling. Dev Cell 53(2):199–211 (e6)
pubmed: 32243782
pmcid: 7236757
Cha Y et al (2017) Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c-SIRT2 axis. Nat Cell Biol 19(5):445–456
pubmed: 28436968
pmcid: 5545746
Moussaieff A et al (2015) Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab 21(3):392–402
pubmed: 25738455
Bulusu V et al (2017) Spatiotemporal analysis of a glycolytic activity gradient linked to mouse embryo mesoderm development. Dev Cell 40(4):331–341 (e4)
pubmed: 28245920
pmcid: 5337618
Oginuma M et al (2017) A gradient of glycolytic activity coordinates FGF and Wnt signaling during elongation of the body axis in amniote embryos. Dev Cell 40(4):342–353 (e10)
pubmed: 28245921
pmcid: 5403012
Amemiya T et al (2022) Glycolytic oscillations in HeLa cervical cancer cell spheroids. FEBS J 289(18):5551–5570
pubmed: 35395137
Kondo H et al (2021) Single-cell resolved imaging reveals intra-tumor heterogeneity in glycolysis, transitions between metabolic states, and their regulatory mechanisms. Cell Rep 34(7):108750
pubmed: 33596424
pmcid: 7900713
Hosios AM et al (2016) Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev Cell 36(5):540–549
pubmed: 26954548
pmcid: 4766004
Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411(6835):375–379
pubmed: 11357145
Orimo A et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3):335–348
pubmed: 15882617
Chen J et al (2011) CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19(4):541–555
pubmed: 21481794
pmcid: 3107500
Rauner G, Kuperwasser C (2021) Microenvironmental control of cell fate decisions in mammary gland development and cancer. Dev Cell 56(13):1875–1883
pubmed: 34256927
Finak G et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14(5):518–527
pubmed: 18438415
Thorsson V et al (2018) The immune landscape of cancer. Immunity 48(4):812–830 (e14)
pubmed: 29628290
pmcid: 5982584
Bareche Y et al (2020) Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach. J Natl Cancer Inst 112(7):708–719
pubmed: 31665482
Chung W et al (2017) Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun 8:15081
pubmed: 28474673
pmcid: 5424158
Nik-Zainal S et al (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149(5):979–993
pubmed: 22608084
pmcid: 3414841
Nik-Zainal S et al (2012) The life history of 21 breast cancers. Cell 149(5):994–1007
pubmed: 22608083
pmcid: 3428864
Wagner J et al (2019) A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 177(5):1330–1345 (e18)
pubmed: 30982598
pmcid: 6526772
Azizi E et al (2018) Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174(5):1293–1308 (e36)
pubmed: 29961579
pmcid: 6348010
Giesen C et al (2014) Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods 11(4):417–422
pubmed: 24584193
Angelo M et al (2014) Multiplexed ion beam imaging of human breast tumors. Nat Med 20(4):436–442
pubmed: 24584119
pmcid: 4110905
Lin JR et al (2018) Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife 7:e31657
Goltsev Y et al (2018) Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. Cell 174(4):968–981 (e15)
pubmed: 30078711
pmcid: 6086938
Ali HR et al (2020) Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. Nat Cancer 1(2):163–175
pubmed: 35122013
Jackson HW et al (2020) The single-cell pathology landscape of breast cancer. Nature 578(7796):615–620
pubmed: 31959985
Danenberg E et al (2022) Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nat Genet 54(5):660–669
pubmed: 35437329
pmcid: 7612730
Sammut SJ et al (2022) Multi-omic machine learning predictor of breast cancer therapy response. Nature 601(7894):623–629
pubmed: 34875674
Krug K et al (2020) Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell 183(5):1436–1456 (e31)
pubmed: 33212010
pmcid: 8077737
Baumann Z, Auf der Maur P, Bentires-Alj M (2022) Feed-forward loops between metastatic cancer cells and their microenvironment-the stage of escalation. EMBO Mol Med 14(6):e14283
pubmed: 35506376
pmcid: 9174884
Li X, Sun X, Carmeliet P (2019) Hallmarks of endothelial cell metabolism in health and disease. Cell Metab 30(3):414–433
pubmed: 31484054
Ryan DG, O’Neill LAJ (2020) Krebs cycle reborn in macrophage immunometabolism. Annu Rev Immunol 38:289–313
pubmed: 31986069
Makowski L, Chaib M, Rathmell JC (2020) Immunometabolism: from basic mechanisms to translation. Immunol Rev 295(1):5–14
pubmed: 32320073
pmcid: 8056251
Plikus MV et al (2021) Fibroblasts: origins, definitions, and functions in health and disease. Cell 184(15):3852–3872
pubmed: 34297930
pmcid: 8566693
Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16(9):582–598
pubmed: 27550820
Sahai E et al (2020) A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 20(3):174–186
pubmed: 31980749
pmcid: 7046529
Almagro J et al (2022) Tissue architecture in tumor initiation and progression. Trends Cancer 8(6):494–505
pubmed: 35300951
de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41(3):374–403
pubmed: 36917948
Arner EN, Rathmell JC (2023) Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 41(3):421–433
pubmed: 36801000
Caligiuri G, Tuveson DA (2023) Activated fibroblasts in cancer: Perspectives and challenges. Cancer Cell 41(3):434–449
pubmed: 36917949
Kamphorst JJ et al (2015) Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res 75(3):544–553
pubmed: 25644265
pmcid: 4316379
Becker LM et al (2020) Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer. Cell Rep 31(9):107701
pubmed: 32492417
pmcid: 7339325
Fiaschi T et al (2012) Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 72(19):5130–5140
pubmed: 22850421
Carmona-Fontaine C et al (2017) Metabolic origins of spatial organization in the tumor microenvironment. Proc Natl Acad Sci USA 114(11):2934–2939
pubmed: 28246332
pmcid: 5358370
Vegran F et al (2011) Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 71(7):2550–2560
pubmed: 21300765
Lee DC et al (2015) A lactate-induced response to hypoxia. Cell 161(3):595–609
pubmed: 25892225
Corchado-Cobos R et al (2022) Pathophysiological integration of metabolic reprogramming in breast cancer. Cancers (Basel) 14(2):322
pubmed: 35053485
Fukano M, Park M, Deblois G (2021) Metabolic flexibility is a determinant of breast cancer heterogeneity and progression. Cancers (Basel) 13(18):4699
pubmed: 34572926
Kung HN, Marks JR, Chi JT (2011) Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet 7(8):e1002229
pubmed: 21852960
pmcid: 3154963
Cao MD et al (2014) Metabolic characterization of triple negative breast cancer. BMC Cancer 14:941
pubmed: 25495193
pmcid: 4295321
Timmerman LA et al (2013) Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24(4):450–465
pubmed: 24094812
pmcid: 3931310
Lukey MJ et al (2016) The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. Nat Commun 7:11321
pubmed: 27089238
pmcid: 4837472
Locasale JW et al (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43(9):869–874
pubmed: 21804546
pmcid: 3677549
Possemato R et al (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476(7360):346–350
pubmed: 21760589
pmcid: 3353325
Park JH et al (2016) Fatty acid oxidation-driven Src links mitochondrial energy reprogramming and oncogenic properties in triple-negative breast cancer. Cell Rep 14(9):2154–2165
pubmed: 26923594
pmcid: 4809061
Kim S, Lee Y, Koo JS (2015) Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS ONE 10(3):e0119473
pubmed: 25751270
pmcid: 4353724
Menendez JA, Lupu R (2017) Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin Ther Targ 21(11):1001–1016
Ferraro GB et al (2021) Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer 2(4):414–428
pubmed: 34179825
pmcid: 8223728
Feng WW et al (2019) CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies. Cell Rep 29(11):3405–3420 (e5)
pubmed: 31825825
pmcid: 6938262
Golden E et al (2021) The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer. Nat Commun 12(1):1920
pubmed: 33772001
pmcid: 7998036
Filippone MG et al (2022) CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer. Nat Commun 13(1):2642
pubmed: 35550508
pmcid: 9098894
Park MK et al (2021) NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. Cell Metab 33(12):2380–2397 (e9)
pubmed: 34879239
pmcid: 8813003
Chakravarty D et al (2014) The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun 5:5383
pubmed: 25415230
Li W et al (2017) The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. J Clin Invest 127(9):3421–3440
pubmed: 28805661
pmcid: 5669564
Craze ML et al (2018) MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. Br J Cancer 118(2):258–265
pubmed: 29169183
Ortmayr K, Dubuis S, Zampieri M (2019) Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism. Nat Commun 10(1):1841
pubmed: 31015463
pmcid: 6478870
Gong Y et al (2021) Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab 33(1):51–64 (e9)
pubmed: 33181091
Zhao N, Rosen JM (2022) Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies. Semin Cancer Biol 82:3–10
pubmed: 34274486
Caswell-Jin JL, Lorenz C, Curtis C (2021) Molecular heterogeneity and evolution in breast cancer. Annu Rev Cancer Biol 5(1):79–94
Shah SP et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395–399
pubmed: 22495314
Glockner S et al (2002) Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 82(10):1419–1426
pubmed: 12379776
Yates LR et al (2015) Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 21(7):751–759
pubmed: 26099045
pmcid: 4500826
Navin N et al (2011) Tumour evolution inferred by single-cell sequencing. Nature 472(7341):90–94
pubmed: 21399628
pmcid: 4504184
Casasent AK et al (2018) Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell 172(1–2):205–217 (e12)
pubmed: 29307488
pmcid: 5766405
Martelotto LG et al (2017) Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. Nat Med 23(3):376–385
pubmed: 28165479
pmcid: 5608257
Davis RT et al (2020) Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. Nat Cell Biol 22(3):310–320
pubmed: 32144411
Dentro SC et al (2021) Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184(8):2239–2254 (e39)
pubmed: 33831375
pmcid: 8054914
Karaayvaz M et al (2018) Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun 9(1):3588
pubmed: 30181541
pmcid: 6123496
Rios AC et al (2019) Intraclonal plasticity in mammary tumors revealed through large-scale single-cell resolution 3D imaging. Cancer Cell 35(4):618–632 (e6)
pubmed: 30930118
Mavrommati I et al (2021) Subclonal heterogeneity and evolution in breast cancer. NPJ Breast Cancer 7(1):155
pubmed: 34934048
pmcid: 8692469
Luond F, Tiede S, Christofori G (2021) Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer 125(2):164–175
pubmed: 33824479
pmcid: 8292450
Singh M et al (2018) Shift from stochastic to spatially-ordered expression of serine-glycine synthesis enzymes in 3D microtumors. Sci Rep 8(1):9388
pubmed: 29925909
pmcid: 6010463
Rossi M et al (2022) PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. Nature 605(7911):747–753
pubmed: 35585241
pmcid: 9888363
Hoxhaj G, Manning BD (2020) The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 20(2):74–88
pubmed: 31686003
Yeo SK et al (2020) Single-cell RNA-sequencing reveals distinct patterns of cell state heterogeneity in mouse models of breast cancer. Elife 9:e58810
Jia D et al (2019) Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways. Proc Natl Acad Sci USA 116(9):3909–3918
pubmed: 30733294
pmcid: 6397570
Aibar S et al (2017) SCENIC: single-cell regulatory network inference and clustering. Nat Methods 14(11):1083–1086
pubmed: 28991892
pmcid: 5937676
Arguello RJ et al (2020) SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution. Cell Metab 32(6):1063–1075 (e7)
pubmed: 33264598
pmcid: 8407169
Hartmann FJ et al (2021) Single-cell metabolic profiling of human cytotoxic T cells. Nat Biotechnol 39(2):186–197
pubmed: 32868913
Rappez L et al (2021) SpaceM reveals metabolic states of single cells. Nat Methods 18(7):799–805
pubmed: 34226721
pmcid: 7611214
Russo E et al (2022) SPICE-Met: profiling and imaging energy metabolism at the single-cell level using a fluorescent reporter mouse. EMBO J 41(19):e111528
pubmed: 35997165
pmcid: 9531294
Ryser MD et al (2019) Cancer outcomes in DCIS patients without locoregional treatment. J Natl Cancer Inst 111(9):952–960
pubmed: 30759222
pmcid: 6748726
Newburger DE et al (2013) Genome evolution during progression to breast cancer. Genome Res 23(7):1097–1108
pubmed: 23568837
pmcid: 3698503
Bergers G, Fendt SM (2021) The metabolism of cancer cells during metastasis. Nat Rev Cancer 21(3):162–180
pubmed: 33462499
pmcid: 8733955
Keren L et al (2018) A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell 174(6):1373–1387 (e19)
pubmed: 30193111
pmcid: 6132072
Risom T et al (2022) Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell 185(2):299–310 (e18)
pubmed: 35063072
pmcid: 8792442
Lomakin A et al (2022) Spatial genomics maps the structure, nature and evolution of cancer clones. Nature 611(7936):594–602
pubmed: 36352222
pmcid: 9668746
Damaghi M et al (2021) The harsh microenvironment in early breast cancer selects for a Warburg phenotype. Proc Natl Acad Sci USA 118(3):e2011342118
pubmed: 33452133
pmcid: 7826394
Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196(4):395–406
pubmed: 22351925
pmcid: 3283993
Xiong G et al (2018) Collagen prolyl 4-hydroxylase 1 is essential for HIF-1alpha stabilization and TNBC chemoresistance. Nat Commun 9(1):4456
pubmed: 30367042
pmcid: 6203834
Xiong G et al (2014) Prolyl-4-hydroxylase alpha subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer 14:1
pubmed: 24383403
pmcid: 3880410
Elia I et al (2019) Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature 568(7750):117–121
pubmed: 30814728
pmcid: 6451642
Faubert B et al (2017) Lactate metabolism in human lung tumors. Cell 171(2):358–371 (e9)
pubmed: 28985563
pmcid: 5684706
Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294(5545):1337–1340
pubmed: 11598268
Abla H et al (2020) The multifaceted contribution of alpha-ketoglutarate to tumor progression: an opportunity to exploit? Semin Cell Dev Biol 98:26–33
pubmed: 31175937
Grigoriadis A et al (2009) CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA 106(32):13493–13498
pubmed: 19651608
pmcid: 2716388
Dornier E et al (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nat Commun 8(1):2255
pubmed: 29269878
pmcid: 5740148
Fidler IJ, Kripke ML (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197(4306):893–895
pubmed: 887927
Husemann Y et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13(1):58–68
pubmed: 18167340
Hosseini H et al (2016) Early dissemination seeds metastasis in breast cancer. Nature 540(7634):552–558
pubmed: 27974799
pmcid: 5390864
Harper KL et al (2016) Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature 540(7634):588–592
pubmed: 27974798
pmcid: 5471138
Hoadley KA et al (2016) Tumor evolution in two patients with basal-like breast cancer: a retrospective genomics study of multiple metastases. PLoS Med 13(12):e1002174
pubmed: 27923045
pmcid: 5140046
Cheung KJ et al (2016) Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci USA 113(7):E854–E863
pubmed: 26831077
pmcid: 4763783
Tiede S et al (2021) Multi-color clonal tracking reveals intra-stage proliferative heterogeneity during mammary tumor progression. Oncogene 40(1):12–27
pubmed: 33046799
Angus L et al (2019) The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet 51(10):1450–1458
pubmed: 31570896
pmcid: 6858873
Ng CKY et al (2017) Genetic heterogeneity in therapy-naive synchronous primary breast cancers and their metastases. Clin Cancer Res 23(15):4402–4415
pubmed: 28351929
pmcid: 5768571
Gui P, Bivona TG (2022) Evolution of metastasis: new tools and insights. Trends Cancer 8(2):98–109
pubmed: 34872888
Ruscitto F et al (2022) Beyond genetics: metastasis as an adaptive response in breast cancer. Int J Mol Sci 23(11):6271
pubmed: 35682953
pmcid: 9181003
Yang J et al (2020) Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 21(6):341–352
pubmed: 32300252
pmcid: 7250738
Nieto MA et al (2016) Emt: 2016. Cell 166(1):21–45
pubmed: 27368099
Aiello NM, Kang Y (2019) Context-dependent EMT programs in cancer metastasis. J Exp Med 216(5):1016–1026
pubmed: 30975895
pmcid: 6504222
Dongre A, Weinberg RA (2019) New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20(2):69–84
pubmed: 30459476
Mani SA et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715
pubmed: 18485877
pmcid: 2728032
Pastushenko I, Blanpain C (2019) EMT transition states during tumor progression and metastasis. Trends Cell Biol 29(3):212–226
pubmed: 30594349
Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14(10):611–629
pubmed: 28397828
pmcid: 5720366
Carey BW et al (2015) Intracellular alpha-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518(7539):413–416
pubmed: 25487152
Gu W et al (2016) Glycolytic metabolism plays a functional role in regulating human pluripotent stem cell state. Cell Stem Cell 19(4):476–490
pubmed: 27618217
pmcid: 5055460
Intlekofer AM, Finley LWS (2019) Metabolic signatures of cancer cells and stem cells. Nat Metab 1(2):177–188
pubmed: 31245788
pmcid: 6594714
Lu V, Roy IJ, Teitell MA (2021) Nutrients in the fate of pluripotent stem cells. Cell Metab 33(11):2108–2121
pubmed: 34644538
pmcid: 8568661
Wang J et al (2009) Dependence of mouse embryonic stem cells on threonine catabolism. Science 325(5939):435–439
pubmed: 19589965
pmcid: 4373593
Zhang H et al (2016) Distinct metabolic states can support self-renewal and lipogenesis in human pluripotent stem cells under different culture conditions. Cell Rep 16(6):1536–1547
pubmed: 27477285
pmcid: 4981511
Montagner M et al (2012) SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 487(7407):380–384
pubmed: 22801492
Kim YJ et al (2021) Suppression of breast cancer progression by FBXL16 via oxygen-independent regulation of HIF1alpha stability. Cell Rep 37(8):109996
pubmed: 34818544
LeBleu VS et al (2014) PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol 16(10):992–1003 (1–15)
pubmed: 25241037
pmcid: 4369153
Bertolini I et al (2020) Small extracellular vesicle regulation of mitochondrial dynamics reprograms a hypoxic tumor microenvironment. Dev Cell 55(2):163–177 (e6)
pubmed: 32780991
pmcid: 7606608
Curtius K, Wright NA, Graham TA (2018) An evolutionary perspective on field cancerization. Nat Rev Cancer 18(1):19–32
pubmed: 29217838
Gameiro PA, Struhl K (2018) Nutrient deprivation elicits a transcriptional and translational inflammatory response coupled to decreased protein synthesis. Cell Rep 24(6):1415–1424
pubmed: 30089253
pmcid: 6419098
Pavlova NN et al (2018) As extracellular glutamine levels decline, asparagine becomes an essential amino acid. Cell Metab 27(2):428–438 (e5)
pubmed: 29337136
pmcid: 5803449
Knott SRV et al (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554(7692):378–381
pubmed: 29414946
pmcid: 5898613
Cherkaoui S et al (2022) A functional analysis of 180 cancer cell lines reveals conserved intrinsic metabolic programs. Mol Syst Biol 18(11):e11033
pubmed: 36321552
pmcid: 9627673
Pece S et al (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1):62–73
pubmed: 20074520
Pece S et al (2019) Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: a retrospective consecutive study. EBioMedicine 42:352–362
pubmed: 30846393
pmcid: 6491379
Yokoi A, Ochiya T (2021) Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology. Semin Cancer Biol 74:79–91
pubmed: 33798721
Mathieu M et al (2019) Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 21(1):9–17
pubmed: 30602770
Liu T et al (2021) Exosomes in breast cancer—mechanisms of action and clinical potential. Mol Cancer Res 19(6):935–945
pubmed: 33627501
pmcid: 8178200
Famta P et al (2022) Enigmatic role of exosomes in breast cancer progression and therapy. Life Sci 289:120210
pubmed: 34875250
Luga V et al (2012) Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 151(7):1542–1556
pubmed: 23260141
Sansone P et al (2017) Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proc Natl Acad Sci USA 114(43):E9066–E9075
pubmed: 29073103
pmcid: 5664494
Rodrigues G et al (2019) Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol 21(11):1403–1412
pubmed: 31685984
pmcid: 7354005
Keklikoglou I et al (2019) Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol 21(2):190–202
pubmed: 30598531
Zhang L et al (2015) Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527(7576):100–104
pubmed: 26479035
pmcid: 4819404
Peinado H et al (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17(5):302–317
pubmed: 28303905
Hoshino A et al (2015) Tumour exosome integrins determine organotropic metastasis. Nature 527(7578):329–335
pubmed: 26524530
pmcid: 4788391
Fong MY et al (2015) Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol 17(2):183–194
pubmed: 25621950
pmcid: 4380143
Morrissey SM et al (2021) Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab 33(10):2040–2058 (e10)
pubmed: 34559989
pmcid: 8506837
Altea-Manzano P et al (2023) A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-kappaB signaling. Nat Cancer 4(3):344–364
pubmed: 36732635
Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168(4):670–691
pubmed: 28187288
pmcid: 5308465
Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8):563–572
pubmed: 12154349
Ramamoorthi G et al (2022) Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. Semin Cancer Biol 78:78–89
pubmed: 33626407
Ring A et al (2022) Clinical and biological aspects of disseminated tumor cells and dormancy in breast cancer. Front Cell Dev Biol 10:929893
pubmed: 35837334
pmcid: 9274007
Phan TG, Croucher PI (2020) The dormant cancer cell life cycle. Nat Rev Cancer 20(7):398–411
pubmed: 32488200
Ghajar CM et al (2013) The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 15(7):807–817
pubmed: 23728425
pmcid: 3826912
Correia AL et al (2021) Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature 594(7864):566–571
pubmed: 34079127
Carlson P et al (2019) Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat Cell Biol 21(2):238–250
pubmed: 30664790
pmcid: 6948102
Paul MR et al (2020) Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J Clin Invest 130(8):4252–4265
pubmed: 32657779
pmcid: 7410083
Yates LR et al (2017) Genomic evolution of breast cancer metastasis and relapse. Cancer Cell 32(2):169–184 (e7)
pubmed: 28810143
pmcid: 5559645
Brown D et al (2017) Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat Commun 8:14944
pubmed: 28429735
pmcid: 5474888
Gundem G et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353–357
pubmed: 25830880
pmcid: 4413032
Roda N, Gambino V, Giorgio M (2020) Metabolic constrains rule metastasis progression. Cells 9(9):2081
pubmed: 32932943
pmcid: 7563739
Bartlome S, Berry CC (2022) Recent insights into the effects of metabolism on breast cancer cell dormancy. Br J Cancer 127(8):1385–1393
pubmed: 35715635
pmcid: 9553927
Kim KH, Lee MS (2014) Autophagy—a key player in cellular and body metabolism. Nat Rev Endocrinol 10(6):322–337
pubmed: 24663220
Leone RD, Amaravadi RK (2013) Autophagy: a targetable linchpin of cancer cell metabolism. Trends Endocrinol Metab 24(4):209–217
pubmed: 23474062
pmcid: 4459128
Anlas AA, Nelson CM (2020) Soft microenvironments induce chemoresistance by increasing autophagy downstream of integrin-linked kinase. Cancer Res 80(19):4103–4113
pubmed: 33008805
pmcid: 7534696
Papalazarou V, Salmeron-Sanchez M, Machesky LM (2018) Tissue engineering the cancer microenvironment-challenges and opportunities. Biophys Rev 10(6):1695–1711
pubmed: 30406572
pmcid: 6297082
Jones BC et al (2022) Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux. Cancer Metastas Rev 41(2):447–458
La Belle Flynn A et al (2019) Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nat Commun 10(1):3668
pubmed: 31413316
pmcid: 6694140
Atsumi T et al (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62(20):5881–5887
pubmed: 12384552
Liang J, Mills GB (2013) AMPK: a contextual oncogene or tumor suppressor? Cancer Res 73(10):2929–2935
pubmed: 23644529
pmcid: 3725287
Domenech E et al (2015) AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. Nat Cell Biol 17(10):1304–1316
pubmed: 26322680
Mihaylova MM, Shaw RJ (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13(9):1016–1023
pubmed: 21892142
pmcid: 3249400
Hampsch RA et al (2020) AMPK activation by metformin promotes survival of dormant ER(+) breast cancer cells. Clin Cancer Res 26(14):3707–3719
pubmed: 32321715
pmcid: 7367755
Li FL et al (2018) Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nat Commun 9(1):508
pubmed: 29410405
pmcid: 5802808
Cantelmo AR et al (2016) Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell 30(6):968–985
pubmed: 27866851
pmcid: 5675554
Gu M et al (2017) PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma. J Cancer 8(18):3887–3896
pubmed: 29151977
pmcid: 5688943
Babaei G, Aziz SG, Jaghi NZZ (2021) EMT, cancer stem cells and autophagy; the three main axes of metastasis. Biomed Pharmacother 133:110909
pubmed: 33227701
Nazio F et al (2019) Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ 26(4):690–702
pubmed: 30728463
pmcid: 6460398
Kim HM, Koo JS (2023) The role of autophagy in breast cancer metastasis. Biomedicines 11(2):618
pubmed: 36831154
pmcid: 9953203
Xu Y, Yang X (2022) Autophagy and pluripotency: self-eating your way to eternal youth. Trends Cell Biol 32(10):868–882
pubmed: 35490141
pmcid: 10433133
Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s–6249s
pubmed: 17062708
Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55(1):61–66
pubmed: 3814476
pmcid: 2001575
Coleman RE et al (2008) Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 14(20):6387–6395
pubmed: 18927277
pmcid: 2763638
Zhang W et al (2021) The bone microenvironment invigorates metastatic seeds for further dissemination. Cell 184(9):2471–2486 (e20)
pubmed: 33878291
pmcid: 8087656
Bado IL et al (2021) The bone microenvironment increases phenotypic plasticity of ER(+) breast cancer cells. Dev Cell 56(8):1100–1117 (e9)
pubmed: 33878299
pmcid: 8062036
Dupuy F et al (2015) PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab 22(4):577–589
pubmed: 26365179
Christen S et al (2016) Breast cancer-derived lung metastases show increased pyruvate carboxylase-dependent anaplerosis. Cell Rep 17(3):837–848
pubmed: 27732858
Roarty K, Echeverria GV (2021) Laboratory models for investigating breast cancer therapy resistance and metastasis. Front Oncol 11:645698
pubmed: 33777805
pmcid: 7988094
Parida PK et al (2022) Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. Cell Metab 34(1):90–105 (e7)
pubmed: 34986341
pmcid: 9307073
Lauby-Secretan B et al (2016) Body fatness and cancer-viewpoint of the IARC working group. N Engl J Med 375(8):794–798
pubmed: 27557308
pmcid: 6754861
Calle EE et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348(17):1625–1638
pubmed: 12711737
Cypess AM (2022) Reassessing human adipose tissue. N Engl J Med 386(8):768–779
pubmed: 35196429
Wang YY et al (2012) Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer. Cancer Lett 324(2):142–151
pubmed: 22643115
Yamaguchi J et al (2008) Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast. Am J Clin Pathol 130(3):382–388
pubmed: 18701411
Seki T et al (2022) Brown-fat-mediated tumour suppression by cold-altered global metabolism. Nature 608(7922):421–428
pubmed: 35922508
pmcid: 9365697
Heer E et al (2020) Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health 8(8):e1027–e1037
pubmed: 32710860
Miller WR, O’Neill J (1987) The importance of local synthesis of estrogen within the breast. Steroids 50(4–6):537–548
pubmed: 3504615
McTiernan A et al (2006) Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring) 14(9):1662–1677
pubmed: 17030978
Simpson E et al (2000) The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab 11(5):184–188
pubmed: 10856920
Picon-Ruiz M et al (2017) Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin 67(5):378–397
pubmed: 28763097
pmcid: 5591063
Neuhouser ML et al (2015) Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol 1(5):611–621
pubmed: 26182172
pmcid: 5070941
Renehan AG, Zwahlen M, Egger M (2015) Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 15(8):484–498
pubmed: 26205341
Santen RJ et al (2009) History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 30(4):343–375
pubmed: 19389994
Qureshi R et al (2020) The major pre- and postmenopausal estrogens play opposing roles in obesity-driven mammary inflammation and breast cancer development. Cell Metab 31(6):1154–1172 (e9)
pubmed: 32492394
Qureshi R et al (2022) Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis. Cell Rep 41(7):111672
pubmed: 36384125
pmcid: 9798480
Bulun SE et al (2005) Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57(3):359–383
pubmed: 16109840
Zhu Q et al (2022) Adipocyte mesenchymal transition contributes to mammary tumor progression. Cell Rep 40(11):111362
pubmed: 36103820
pmcid: 9533474
Onuchic V et al (2016) Epigenomic deconvolution of breast tumors reveals metabolic coupling between constituent cell types. Cell Rep 17(8):2075–2086
pubmed: 27851969
pmcid: 5115176
Bochet L et al (2013) Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res 73(18):5657–5668
pubmed: 23903958
Dirat B et al (2011) Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 71(7):2455–2465
pubmed: 21459803
Wilson-Fritch L et al (2003) Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 23(3):1085–1094
pubmed: 12529412
pmcid: 140688
Nieman KM et al (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17(11):1498–1503
pubmed: 22037646
pmcid: 4157349
Wang YY et al (2017) Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. JCI Insight 2(4):e87489
pubmed: 28239646
pmcid: 5313068
Zhang L, Bu P (2022) The two sides of creatine in cancer. Trends Cell Biol 32(5):380–390
pubmed: 34895811
Kurmi K et al (2018) Tyrosine phosphorylation of mitochondrial creatine kinase 1 enhances a druggable tumor energy shuttle pathway. Cell Metab 28(6):833–847 (e8)
pubmed: 30174304
pmcid: 6281770
Maguire OA et al (2021) Creatine-mediated crosstalk between adipocytes and cancer cells regulates obesity-driven breast cancer. Cell Metab 33(3):499–512 (e6)
pubmed: 33596409
pmcid: 7954401
Huang CK et al (2017) Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via beta-hydroxybutyrate. Nat Commun 8:14706
pubmed: 28281525
pmcid: 5353665
Shimazu T et al (2013) Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339(6116):211–214
pubmed: 23223453
Wang QA et al (2018) Reversible de-differentiation of mature white adipocytes into preadipocyte-like precursors during lactation. Cell Metab 28(2):282–288 (e3)
pubmed: 29909970
pmcid: 6535147
Lynch SV, Pedersen O (2016) The human intestinal microbiome in health and disease. N Engl J Med 375(24):2369–2379
pubmed: 27974040
Rooks MG, Garrett WS (2016) Gut microbiota, metabolites and host immunity. Nat Rev Immunol 16(6):341–352
pubmed: 27231050
pmcid: 5541232
Thomas S et al (2017) The host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists. Cancer Res 77(8):1783–1812
pubmed: 28292977
pmcid: 5392374
Megraud F (2005) A humble bacterium sweeps this year’s Nobel Prize. Cell 123(6):975–976
pubmed: 16360024
Sepich-Poore GD et al (2021) The microbiome and human cancer. Science 371(6536):eabc4552
pubmed: 33766858
pmcid: 8767999
Helmink BA et al (2019) The microbiome, cancer, and cancer therapy. Nat Med 25(3):377–388
pubmed: 30842679
Sears CL, Garrett WS (2014) Microbes, microbiota, and colon cancer. Cell Host Microb 15(3):317–328
Gopalakrishnan V et al (2018) The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 33(4):570–580
pubmed: 29634945
pmcid: 6529202
Kwa M et al (2016) The intestinal microbiome and estrogen receptor-positive female breast cancer. J Natl Cancer Inst 108(8):djw029
pubmed: 27107051
pmcid: 5017946
Urbaniak C et al (2016) The microbiota of breast tissue and its association with breast cancer. Appl Environ Microbiol 82(16):5039–5048
pubmed: 27342554
pmcid: 4968547
Liu NN et al (2022) Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. Nat Microbiol 7(2):238–250
pubmed: 35087227
pmcid: 8813618
Narunsky-Haziza L et al (2022) Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell 185(20):3789–3806 (e17)
pubmed: 36179670
pmcid: 9567272
Dohlman AB et al (2022) A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell 185(20):3807–3822 (e12)
pubmed: 36179671
Cao Z et al (2022) The gut virome: a new microbiome component in health and disease. EBioMedicine 81:104113
pubmed: 35753153
pmcid: 9240800
Gur C et al (2015) Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42(2):344–355
pubmed: 25680274
pmcid: 4361732
Yachida S et al (2019) Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med 25(6):968–976
pubmed: 31171880
Tanoue T et al (2019) A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565(7741):600–605
pubmed: 30675064
Zitvogel L et al (2018) The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 359(6382):1366–1370
pubmed: 29567708
Kadosh E et al (2020) The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature 586(7827):133–138
pubmed: 32728212
pmcid: 7116712
Ma C et al (2018) Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360(6391):eaan5931
pubmed: 29798856
pmcid: 6407885
Chambers ES et al (2018) Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Curr Nutr Rep 7(4):198–206
pubmed: 30264354
pmcid: 6244749
Barki N et al (2022) Chemogenetics defines a short-chain fatty acid receptor gut-brain axis. Elife 11:e73777
pubmed: 35229717
pmcid: 8887895
Jaye K et al (2022) The role of key gut microbial metabolites in the development and treatment of cancer. Gut Microb 14(1):2038865
Okumura S et al (2021) Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion. Nat Commun 12(1):5674
pubmed: 34584098
pmcid: 8479117
Matsushita M et al (2021) Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF1 signaling. Cancer Res 81(15):4014–4026
pubmed: 34039634
Bultman SJ, Jobin C (2014) Microbial-derived butyrate: an oncometabolite or tumor-suppressive metabolite? Cell Host Microbe 16(2):143–145
pubmed: 25121740
pmcid: 4179296
Belcheva A et al (2014) Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 158(2):288–299
pubmed: 25036629
Singh V et al (2018) Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell 175(3):679–694 (e22)
pubmed: 30340040
pmcid: 6232850
Sabari BR et al (2017) Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol 18(2):90–101
pubmed: 27924077
Shrode RL et al (2023) Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria. Sci Rep 13(1):526
pubmed: 36631533
pmcid: 9834383
Wang N et al (2022) Identifying distinctive tissue and fecal microbial signatures and the tumor-promoting effects of deoxycholic acid on breast cancer. Front Cell Infect Microbiol 12:1029905
pubmed: 36583106
pmcid: 9793878
Zhu J et al (2018) Breast cancer in postmenopausal women is associated with an altered gut metagenome. Microbiome 6(1):136
pubmed: 30081953
pmcid: 6080540
Buchta Rosean C et al (2019) Preexisting commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer. Cancer Res 79(14):3662–3675
pubmed: 31064848
McKee AM et al (2021) Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth. iScience 24(9):103012
pubmed: 34522855
pmcid: 8426205
Zhang X et al (2021) Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis. Sci Rep 11(1):14024
pubmed: 34234229
pmcid: 8263554
Routy B et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91–97
pubmed: 29097494
Plottel CS, Blaser MJ (2011) Microbiome and malignancy. Cell Host Microb 10(4):324–335
Komorowski AS, Pezo RC (2020) Untapped “-omics”: the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment. Breast Cancer Res Treat 179(2):287–300
pubmed: 31646389
Hanker AB, Sudhan DR, Arteaga CL (2020) Overcoming endocrine resistance in breast cancer. Cancer Cell 37(4):496–513
pubmed: 32289273
pmcid: 7169993
Shiao SL et al (2021) Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer Cell 39(9):1202–1213 (e6)
pubmed: 34329585
pmcid: 8830498
Iliev ID, Cadwell K (2021) Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases. Gastroenterology 160(4):1050–1066
pubmed: 33347881
Nejman D et al (2020) The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368(6494):973–980
pubmed: 32467386
pmcid: 7757858
Poore GD et al (2020) Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 579(7800):567–574
pubmed: 32214244
pmcid: 7500457
Jin C et al (2019) Commensal microbiota promote lung cancer development via gammadelta T cells. Cell 176(5):998–1013 (e16)
pubmed: 30712876
pmcid: 6691977
Riquelme E et al (2019) Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178(4):795–806 (e12)
pubmed: 31398337
pmcid: 7288240
Urbaniak C et al (2014) Microbiota of human breast tissue. Appl Environ Microbiol 80(10):3007–3014
pubmed: 24610844
pmcid: 4018903
Shively CA et al (2018) Consumption of mediterranean versus western diet leads to distinct mammary gland microbiome populations. Cell Rep 25(1):47–56 (e3)
pubmed: 30282037
pmcid: 6338220
Hieken TJ et al (2016) The microbiome of aseptically collected human breast tissue in benign and malignant disease. Sci Rep 6:30751
pubmed: 27485780
pmcid: 4971513
Buckland G et al (2013) Adherence to the Mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study. Int J Cancer 132(12):2918–2927
pubmed: 23180513
Castello A et al (2014) Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study. Br J Cancer 111(7):1454–1462
pubmed: 25101568
pmcid: 4183855
Banerjee S et al (2021) Prognostic correlations with the microbiome of breast cancer subtypes. Cell Death Dis 12(9):831
pubmed: 34482363
pmcid: 8418604
Brennan CA, Garrett WS (2019) Fusobacterium nucleatum—symbiont, opportunist and oncobacterium. Nat Rev Microbiol 17(3):156–166
pubmed: 30546113
pmcid: 6589823
Abed J et al (2016) Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe 20(2):215–225
pubmed: 27512904
pmcid: 5465824
Parhi L et al (2020) Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun 11(1):3259
pubmed: 32591509
pmcid: 7320135
Jiang YZ et al (2019) Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell 35(3):428–440 (e5)
pubmed: 30853353
Wang H et al (2022) The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab 34(4):581–594 (e8)
pubmed: 35278352
Alam A et al (2022) Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell 40(2):153–167 (e11)
pubmed: 35120601
pmcid: 8847236
Aykut B et al (2019) The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature 574(7777):264–267
pubmed: 31578522
pmcid: 6858566
Bullman S et al (2017) Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358(6369):1443–1448
pubmed: 29170280
pmcid: 5823247
Cullin N et al (2021) Microbiome and cancer. Cancer Cell 39(10):1317–1341
pubmed: 34506740
Fu A et al (2022) Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell 185(8):1356–1372 (e26)
pubmed: 35395179
Dieleman S et al (2021) Exploring the potential of breast microbiota as biomarker for breast cancer and therapeutic response. Am J Pathol 191(6):968–982
pubmed: 33713687
Stein EM et al (2017) Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6):722–731
pubmed: 28588020
pmcid: 5572791
Figueroa ME et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6):553–567
pubmed: 21130701
pmcid: 4105845
Turcan S et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390):479–483
pubmed: 22343889
pmcid: 3351699
Stine ZE et al (2022) Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov 21(2):141–162
pubmed: 34862480
Lemberg KM et al (2022) Clinical development of metabolic inhibitors for oncology. J Clin Invest 132(1):e148550
Kumar A et al (2023) Targeting epigenetic regulation for cancer therapy using small molecule inhibitors. Adv Cancer Res 158:73–161
pubmed: 36990539
Corsello SM et al (2020) Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer 1(2):235–248
pubmed: 32613204
pmcid: 7328899
Jin MZ, Jin WL (2020) The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther 5(1):166
pubmed: 32843638
pmcid: 7447642
Leone RD et al (2019) Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science 366(6468):1013–1021
pubmed: 31699883
pmcid: 7023461
Pinkus LM (1977) Glutamine binding sites. Methods Enzymol 46:414–427
pubmed: 909432